Your cart is empty.
Laboratories working in the field of in vitro diagnostics (IVD) must comply with increasing accreditation requirements that may vary from country to country. For US-based Inova Diagnostics, the challenge was to provide a family of automated platforms that make it easy for labs to conform with accreditation requirements for autoimmune testing.
In vitro diagnostics (IVD) is central to the provision of healthcare globally, and is estimated to be worth in excess of $8.2 billion (€7.3 billion) a year in China alone.1 Despite this, the Chinese IVD landscape has historically been controlled by large international providers, with few domestic instrumentation and assay suppliers. Start-up company Shenzen AiTe is looking to change this, with the development of diagnostic platforms and assays offering rapid detection for a wide range of blood-based markers.